NXP-3P Reta: What This Research Peptide Actually Is

NXP-3P reta is a supplier catalog label for research-grade retatrutide, a triple-agonist peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is not an FDA-approved drug, and vials sold under this name are labeled for laboratory research rather than human use. If you searched this term, the useful answer is simple: NXP-3P is a product code, while retatrutide is the actual molecule behind it.

What the Name "NXP-3P Reta" Actually Means

Research peptide vendors invent their own SKU names to differentiate listings, and NXP-3P appears to be one of them. The 3P designation typically points to a three-pathway product, which lines up with retatrutide's triple-receptor activity. Reta is simply industry shorthand for retatrutide, the compound Eli Lilly has developed under the code LY3437943.

Because supplier naming is not standardized, two vendors can sell chemically identical retatrutide under completely different labels. The name printed on a vial tells you very little about what is inside it.

Before trusting any NXP-3P reta listing, check for these items:

• A batch-specific certificate of analysis (COA) from an independent laboratory
• HPLC purity data, generally 98% or higher for research peptides
• Mass spectrometry confirmation matching the expected molecular weight
• Clear storage, reconstitution, and handling instructions
• An explicit research-use-only disclaimer

How Retatrutide Works in Research Settings

Retatrutide is a single peptide that binds three receptors at once. GLP-1 and GIP activity drives appetite suppression and improved glucose handling, while glucagon receptor activation adds energy-expenditure effects that separate it from semaglutide and tirzepatide.

The most-cited human data comes from a Phase 2 trial published in The New England Journal of Medicine in 2023. Adults with obesity received weekly injections for 48 weeks, and participants on the highest dose lost an average of roughly 24% of their body weight.

Those results describe an investigational drug given under close medical supervision, not a research chemical bought online. Trial volunteers were screened for contraindications and dosed on a strict escalation schedule that most self-directed users do not replicate.

NXP-3P Reta vs. Other Research Stacks

People comparing cagri and reta are essentially weighing an amylin analog against a triple incretin agonist, and the two act through different appetite pathways. The table below outlines how the most common reta-based research stacks differ on paper.

Research approach	Receptor targets	Human data available	Reported results	Regulatory status in the US
NXP-3P reta (retatrutide alone)	GLP-1, GIP, glucagon	Phase 2 and Phase 3 trials	About 24% average weight reduction at 48 weeks on 12 mg weekly	Not FDA-approved
Reta plus cagrilintide	Triple agonist plus amylin/calcitonin receptors	No published combination trial	Unknown; promoted as broader appetite control	Neither compound approved for this use
Reta plus MOTS-c	Triple agonist plus mitochondrial-derived peptide	No human trials of the combination	Anecdotal reports only	Niether compound approved for this use

Two details stand out. Retatrutide is the only item in that table supported by large published human trials, and no combination listed has been tested together in a controlled study.

Reported Side Effects and Safety Signals

Gastrointestinal effects dominated the retatrutide Phase 2 data. Nausea, diarrhea, vomiting, and constipation were the most frequent complaints, and they appeared to be dose-dependent, with the 12 mg group reporting more than the 1 mg group.

Other signals included a modest rise in resting heart rate, injection-site reactions, and gallbladder-related events in a small number of participants. These fall into the same risk categories seen with other incretin-based medications.

Suppliers often advertise cagri reta blend benefits such as stronger appetite suppression, but those are marketing claims rather than trial findings. Without published combination data, the additive risk of two appetite-suppressing peptides is simply unknown.

Likewise, reported reta and mots-c stack side effects in user forums are anecdotal and cannot be verified. MOTS-c has no established human safety profile, so adding it introduces an entirely unmeasured variable.

Dosing, Handling, and Realistic Expectations

There is no established human dose for NXP-3P reta. In trials, retatrutide was injected once weekly with gradual escalation, but those doses were designed for a regulated clinical program, not for self-administration.

The same gap applies to combinations. No peer-reviewed protocol defines a reta and mots-c stack dosage, and the reta vs mots-c comparison is uneven because MOTS-c has no large human trials behind it at all.

Handling matters just as much as dosing. Most research peptides ship as lyophilized powder and should be refrigerated, protected from light, and reconstituted with bacteriostatic water in a clean environment.

Legal Status and Vendor Quality Checks

Retatrutide is not approved by the FDA for any indication, and it does not appear on the agency's list of bulk drug substances that may be used in compounding. As a result, licensed 503A pharmacies cannot legally compound it.

Research vials sold under labels like NXP-3P reta exist outside that framework, which means they carry no guarantee of purity, potency, or sterility. The only meaningful verification is an independent certificate of analysis tied to the specific batch number.

Anyone weighing use of an unapproved peptide should speak with a licensed healthcare professional first, especially if they take prescription medication, have a history of pancreatitis, or are pregnant or breastfeeding. Nothing here is medical advice.

COMMON QUESTIONS

Frequently Asked Questions

What is NXP-3P reta?

NXP-3P reta is a supplier catalog name for research-grade retatrutide, a triple-agonist peptide that targets the GLP-1, GIP, and glucagon receptors. It is not a distinct drug or a government-recognized chemical name, and vials sold under this label are marked for laboratory research only. Because vendor naming is not standardized, the same molecule can appear under several different product codes.

Is NXP-3P reta FDA-approved for weight loss?

No. Retatrutide has not been approved by the FDA for any indication, including weight loss, and it does not appear on the agency's list of bulk substances that compounding pharmacies may legally use. It remains an investigational drug studied in trials sponsored by its manufacturer. Any product advertised as NXP-3P reta for human use is being sold outside FDA oversight.

What side effects have been reported with retatrutide?

In published Phase 2 data, the most common effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation, with higher rates at higher doses. Researchers also noted modest increases in resting heart rate, injection-site reactions, and rare gallbladder-related events. Long-term safety data are still being collected, and no combination with cagrilintide or MOTS-c has been tested in humans.